Who are Montanide ISA 51 VG's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): H5N1 vaccine (Arepanrix), MgSO4 plus Ropivacaine, Licensed seasonal influenza vaccine, ropivacaine plus clonidine, Perineural Dexamethasone and bupivacaine, adjuvanted Arepanrix.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/montanide-isa-51-vg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Montanide ISA 51 VG — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Montanide ISA 51 VG (Montanide ISA 51 VG) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: adjuvant. Area: Oncology.

phase 3 adjuvant Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Montanide ISA 51 VG (Montanide ISA 51 VG) — National Cancer Institute (NCI). Montanide ISA 51 VG is an adjuvant used to enhance the immune response to vaccines.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Montanide ISA 51 VG TARGET	Montanide ISA 51 VG	National Cancer Institute (NCI)	phase 3	adjuvant
H5N1 vaccine (Arepanrix)	H5N1 vaccine (Arepanrix)	Canadian Immunization Research Network	marketed	inactivated split-virion influenza vaccine with adjuvant
MgSO4 plus Ropivacaine	MgSO4 plus Ropivacaine	Hospital Universiti Sains Malaysia	marketed	Local anesthetic adjuvant combination	Voltage-gated sodium channels (ropivacaine); NMDA receptors and calcium channels (magnesium sulfate)
Licensed seasonal influenza vaccine	Licensed seasonal influenza vaccine	Novavax	marketed	Recombinant protein vaccine with adjuvant	Influenza hemagglutinin (HA) protein
ropivacaine plus clonidine	ropivacaine plus clonidine	University Hospital, Lille	marketed	Local anesthetic with adjuvant alpha-2 agonist	Voltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (clonidine)
Perineural Dexamethasone and bupivacaine	Perineural Dexamethasone and bupivacaine	Sherif Mohamed Abd el moneim Soaida, MD	marketed	Local anesthetic with adjuvant corticosteroid	Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (adjuvant class)

National Cancer Institute (NCI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Montanide ISA 51 VG — Competitive Intelligence Brief. https://druglandscape.com/ci/montanide-isa-51-vg. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab